| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 17 | 2023 | 275 | 6.490 |
Why?
|
| Hepatitis B virus | 13 | 2023 | 225 | 4.440 |
Why?
|
| Hepatitis B, Chronic | 11 | 2022 | 139 | 4.090 |
Why?
|
| Virus Activation | 11 | 2022 | 236 | 2.980 |
Why?
|
| Hepatitis C | 7 | 2024 | 549 | 2.010 |
Why?
|
| Antiviral Agents | 12 | 2022 | 1253 | 1.930 |
Why?
|
| Mass Screening | 18 | 2024 | 1549 | 1.780 |
Why?
|
| Neoplasms | 27 | 2023 | 15919 | 1.750 |
Why?
|
| Hepacivirus | 7 | 2024 | 423 | 1.350 |
Why?
|
| HIV Infections | 5 | 2023 | 2155 | 1.090 |
Why?
|
| Hepatitis C, Chronic | 6 | 2024 | 471 | 1.050 |
Why?
|
| Alphapapillomavirus | 3 | 2022 | 172 | 1.010 |
Why?
|
| Hepatitis B Core Antigens | 3 | 2020 | 28 | 0.930 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2013 | 1233 | 0.860 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 7017 | 0.840 |
Why?
|
| Hepatitis C Antibodies | 3 | 2024 | 49 | 0.840 |
Why?
|
| Antineoplastic Agents | 10 | 2022 | 14616 | 0.830 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 7 | 2024 | 444 | 0.810 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 1431 | 0.690 |
Why?
|
| Hepatitis B Surface Antigens | 6 | 2023 | 89 | 0.670 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2021 | 1903 | 0.660 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 1340 | 0.610 |
Why?
|
| Rituximab | 3 | 2021 | 1593 | 0.600 |
Why?
|
| Immunization, Passive | 1 | 2018 | 188 | 0.600 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 191 | 0.580 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 1067 | 0.550 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 719 | 0.540 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2024 | 2175 | 0.540 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 1301 | 0.520 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 1955 | 0.520 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 1387 | 0.510 |
Why?
|
| Liver Neoplasms | 5 | 2024 | 4820 | 0.510 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 999 | 0.460 |
Why?
|
| Humans | 64 | 2024 | 270802 | 0.450 |
Why?
|
| Aged | 27 | 2024 | 73382 | 0.430 |
Why?
|
| Adult | 30 | 2022 | 81997 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 878 | 0.400 |
Why?
|
| Middle Aged | 29 | 2024 | 90347 | 0.400 |
Why?
|
| Resuscitation Orders | 3 | 2009 | 70 | 0.390 |
Why?
|
| Mothers | 2 | 2018 | 416 | 0.390 |
Why?
|
| Cancer Care Facilities | 2 | 2013 | 907 | 0.370 |
Why?
|
| Acculturation | 4 | 2013 | 110 | 0.370 |
Why?
|
| Vaginal Smears | 2 | 2021 | 166 | 0.360 |
Why?
|
| Prevalence | 8 | 2022 | 3402 | 0.350 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 247 | 0.350 |
Why?
|
| Risk Factors | 9 | 2023 | 17900 | 0.340 |
Why?
|
| Qualitative Research | 5 | 2024 | 636 | 0.330 |
Why?
|
| Hepatitis B Vaccines | 2 | 2018 | 50 | 0.330 |
Why?
|
| Attitude to Health | 1 | 2012 | 434 | 0.330 |
Why?
|
| Female | 35 | 2024 | 148967 | 0.330 |
Why?
|
| Vietnam | 4 | 2013 | 65 | 0.320 |
Why?
|
| Patient Care | 1 | 2010 | 148 | 0.320 |
Why?
|
| Young Adult | 12 | 2020 | 22225 | 0.320 |
Why?
|
| Community Health Services | 1 | 2010 | 128 | 0.310 |
Why?
|
| Liver Cirrhosis | 4 | 2021 | 1046 | 0.310 |
Why?
|
| Hepatitis B Antibodies | 4 | 2023 | 57 | 0.310 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 2484 | 0.310 |
Why?
|
| Hepatitis | 1 | 2009 | 92 | 0.310 |
Why?
|
| Adolescent | 13 | 2021 | 32743 | 0.310 |
Why?
|
| Male | 28 | 2024 | 128397 | 0.290 |
Why?
|
| Liver Failure | 2 | 2019 | 141 | 0.290 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2009 | 100 | 0.290 |
Why?
|
| Universities | 1 | 2008 | 159 | 0.280 |
Why?
|
| Documentation | 2 | 2008 | 213 | 0.280 |
Why?
|
| Survivors | 1 | 2012 | 1023 | 0.280 |
Why?
|
| Focus Groups | 3 | 2012 | 282 | 0.270 |
Why?
|
| Incidence | 5 | 2024 | 5828 | 0.270 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2009 | 346 | 0.260 |
Why?
|
| Students | 1 | 2008 | 332 | 0.250 |
Why?
|
| Recurrence | 3 | 2021 | 4877 | 0.250 |
Why?
|
| Emergency Service, Hospital | 2 | 2009 | 1252 | 0.240 |
Why?
|
| Health Personnel | 1 | 2010 | 652 | 0.230 |
Why?
|
| Referral and Consultation | 1 | 2010 | 931 | 0.230 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 900 | 0.220 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 3044 | 0.210 |
Why?
|
| Retrospective Studies | 11 | 2022 | 39832 | 0.210 |
Why?
|
| Interprofessional Relations | 1 | 2004 | 205 | 0.210 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 102 | 0.210 |
Why?
|
| Alanine Transaminase | 2 | 2021 | 239 | 0.200 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 417 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 4498 | 0.200 |
Why?
|
| Texas | 6 | 2013 | 6447 | 0.190 |
Why?
|
| Papillomaviridae | 2 | 2022 | 636 | 0.190 |
Why?
|
| United States | 8 | 2023 | 15855 | 0.190 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 116 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2023 | 13417 | 0.180 |
Why?
|
| Guanine | 1 | 2021 | 157 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2020 | 67 | 0.180 |
Why?
|
| Liver Transplantation | 1 | 2009 | 1195 | 0.170 |
Why?
|
| Advisory Committees | 1 | 2020 | 196 | 0.170 |
Why?
|
| Emergency Medical Services | 1 | 2004 | 469 | 0.170 |
Why?
|
| Quality of Life | 3 | 2021 | 4775 | 0.170 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 209 | 0.170 |
Why?
|
| RNA, Viral | 2 | 2020 | 730 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 257 | 0.160 |
Why?
|
| Decision Trees | 1 | 2019 | 181 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2020 | 311 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 16669 | 0.160 |
Why?
|
| Life Style | 1 | 2022 | 618 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 236 | 0.150 |
Why?
|
| Electronic Health Records | 2 | 2024 | 850 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 1199 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2012 | 5676 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2021 | 9474 | 0.140 |
Why?
|
| Glucokinase | 1 | 2016 | 23 | 0.140 |
Why?
|
| Adenine | 1 | 2019 | 672 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 1129 | 0.130 |
Why?
|
| Medicare | 1 | 2021 | 926 | 0.130 |
Why?
|
| Sex Distribution | 1 | 2017 | 497 | 0.130 |
Why?
|
| Leukemia | 1 | 2004 | 1719 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2017 | 749 | 0.130 |
Why?
|
| Age Distribution | 1 | 2017 | 727 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 2394 | 0.120 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 32 | 0.120 |
Why?
|
| Hepatitis B Antigens | 2 | 2015 | 16 | 0.120 |
Why?
|
| Nutrition Surveys | 3 | 2022 | 317 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2020 | 822 | 0.120 |
Why?
|
| SEER Program | 1 | 2019 | 1047 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 965 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2019 | 799 | 0.120 |
Why?
|
| Graft vs Host Disease | 2 | 2018 | 2808 | 0.120 |
Why?
|
| Piperidines | 1 | 2019 | 1098 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 31008 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2018 | 717 | 0.110 |
Why?
|
| Methylphenidate | 1 | 2014 | 91 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1414 | 0.110 |
Why?
|
| Decision Making | 2 | 2019 | 1251 | 0.110 |
Why?
|
| Mother-Child Relations | 1 | 2013 | 85 | 0.110 |
Why?
|
| Korea | 1 | 2012 | 64 | 0.110 |
Why?
|
| Intention | 1 | 2013 | 114 | 0.110 |
Why?
|
| Grounded Theory | 1 | 2012 | 10 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 2045 | 0.100 |
Why?
|
| Rheumatic Diseases | 1 | 2013 | 100 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 794 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 914 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2016 | 392 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2021 | 6237 | 0.100 |
Why?
|
| Disease Progression | 3 | 2018 | 6855 | 0.090 |
Why?
|
| China | 1 | 2012 | 635 | 0.090 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 197 | 0.090 |
Why?
|
| Sex Factors | 2 | 2008 | 2184 | 0.090 |
Why?
|
| Body Image | 1 | 2011 | 123 | 0.090 |
Why?
|
| Data Collection | 2 | 2011 | 608 | 0.090 |
Why?
|
| Liver | 2 | 2018 | 3089 | 0.090 |
Why?
|
| Comorbidity | 1 | 2017 | 2392 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2012 | 521 | 0.090 |
Why?
|
| Medical Oncology | 2 | 2019 | 1465 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 598 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2012 | 756 | 0.090 |
Why?
|
| Cultural Characteristics | 1 | 2010 | 67 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4480 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1417 | 0.080 |
Why?
|
| Polypharmacy | 1 | 2009 | 62 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2013 | 847 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2015 | 1320 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 855 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 607 | 0.080 |
Why?
|
| Survival | 1 | 2009 | 183 | 0.080 |
Why?
|
| Fibrosis | 2 | 2022 | 733 | 0.080 |
Why?
|
| Research Design | 1 | 2016 | 1569 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 599 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 5102 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 152 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 2209 | 0.080 |
Why?
|
| Advance Care Planning | 1 | 2009 | 93 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 218 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 2009 | 255 | 0.070 |
Why?
|
| Fatigue | 1 | 2014 | 1279 | 0.070 |
Why?
|
| Body Weight | 1 | 2011 | 1311 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 1109 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 852 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 4140 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2014 | 1697 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 5591 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2017 | 9290 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 2222 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2017 | 6768 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 625 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1457 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2004 | 106 | 0.060 |
Why?
|
| Benchmarking | 1 | 2005 | 275 | 0.060 |
Why?
|
| Child | 4 | 2018 | 30546 | 0.050 |
Why?
|
| Time Factors | 1 | 2017 | 13021 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2004 | 261 | 0.050 |
Why?
|
| Algorithms | 1 | 2013 | 3900 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2023 | 376 | 0.050 |
Why?
|
| Outpatients | 1 | 2004 | 463 | 0.050 |
Why?
|
| Respiratory Insufficiency | 1 | 2004 | 345 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 45 | 0.050 |
Why?
|
| Social Support | 1 | 2024 | 590 | 0.050 |
Why?
|
| Poverty | 1 | 2024 | 486 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 1265 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2022 | 255 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2004 | 381 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 5923 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2021 | 247 | 0.040 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 186 | 0.040 |
Why?
|
| Prognosis | 2 | 2009 | 22481 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 689 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 3707 | 0.040 |
Why?
|
| Age Factors | 1 | 2008 | 5465 | 0.040 |
Why?
|
| Adipokines | 1 | 2018 | 96 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2014 | 8699 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2019 | 33741 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2018 | 241 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 47 | 0.030 |
Why?
|
| Survival Rate | 1 | 2009 | 12527 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2018 | 439 | 0.030 |
Why?
|
| Counseling | 1 | 2018 | 381 | 0.030 |
Why?
|
| Sulfonylurea Receptors | 1 | 2014 | 23 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 182 | 0.030 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2014 | 54 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 13989 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2018 | 646 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 1207 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1480 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 1884 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 190 | 0.030 |
Why?
|
| Carcinoma | 1 | 2004 | 2609 | 0.030 |
Why?
|
| Global Health | 1 | 2018 | 689 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 443 | 0.030 |
Why?
|
| Genotype | 1 | 2021 | 4255 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2018 | 732 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 195 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1089 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 5171 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 452 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 3448 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 12028 | 0.020 |
Why?
|
| Animals | 2 | 2012 | 62048 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3194 | 0.020 |
Why?
|
| Smoking | 1 | 2019 | 2555 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 16205 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 136 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2588 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2004 | 17048 | 0.020 |
Why?
|
| Terminally Ill | 1 | 2008 | 97 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 2496 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4831 | 0.020 |
Why?
|
| Obesity | 1 | 2019 | 2905 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 15212 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6516 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 7383 | 0.010 |
Why?
|
| Palliative Care | 1 | 2008 | 2178 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 15911 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 12102 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 35597 | 0.010 |
Why?
|